The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
HLA class I and II genotype of the NCI-60 cell lines
Open accessAbstract
Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although HLA typing continues to be used for authentication, it can be difficult to compare early results based on serology19 with later results from sequence‐based typing.43”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
The National Cancer Institute: cancer drug discovery and development program.
Grever, M. R., Schepartz, S. A., & Chabner, B. A. (1992) · PubMed · Cited by 722
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Chemosensitivity prediction by transcriptional profiling
Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191368598 · Cited by 684
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Cited by
The evolving translational potential of small extracellular vesicles in cancer
Möller, A., & Lobb, R. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00299-w · Cited by 544
HLA typing from RNA-Seq sequence reads
Boegel, S., Löwer, M., Schäfer, M., Bukur, T., de Graaf, J., Boisguérin, V., Türeci, Ö., Diken, M., Castle, J. C., & Sahin, U. (2012) · Genome Medicine · doi:10.1186/gm403 · Cited by 270
Korch, C., Hall, E. M., Dirks, W. G., Ewing, M., Faries, M., Varella‐Garcia, M., Robinson, S., Storts, D., Turner, J. A., Wang, Y., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31067 · Cited by 54
“Although HLA typing continues to be used for authentication, it can be difficult to compare early results based on serology(19) with later results from sequence-based typing.(43) STR profiling of early passage samples offers an effective solution, enabling comparison of samples from different laboratories, and its use…”
ResultDevelopment of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Li, D., Bentley, C., Anderson, A., Wiblin, S., Cleary, K. L. S., Koustoulidou, S., Hassanali, T., Yates, J., Greig, J., Nordkamp, M. O., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3247 · Cited by 38
Metadata
- Authors
- Adams, S., Robbins, F.-M., Chen, D., Wagage, D., Holbeck, S. L., Morse, H. C., Stroncek, D., & Marincola, F. M.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- National Institute of Allergy and Infectious Diseases (US)
- Corresponding author
- Marincola, Francesco M
- Venue
- Journal of Translational Medicine
- Published
- 2005-03-04
- Volume
- 3
- Issue
- 1
- Pages
- 11-11
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC555742
- OpenAlex
- W2104519476
- Cited by
- 68
- References
- 48
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- NCI-60 cell lines, human leukocyte antigen, HLA class I, HLA class II, HLA genotypes, sequence-based typing, cancer cell lines, cell line contamination, antigen presentation, drug screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HLA class I and II genotype of the NCI-60 cell lines. https://app.cochat.ai/papers/10.1186/1479-5876-3-11
- The paper
- Adams, S., Robbins, F.-M., Chen, D., Wagage, D., Holbeck, S. L., Morse, H. C., Stroncek, D., & Marincola, F. M. (2005). HLA class I and II genotype of the NCI-60 cell lines. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-3-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.